NASDAQ:AGRX

Agile Therapeutics Competitors

$1.90
+0.03 (+1.60 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.89
Now: $1.90
$1.97
50-Day Range
$1.88
MA: $2.25
$3.13
52-Week Range
$1.85
Now: $1.90
$3.89
Volume808,544 shs
Average Volume1.57 million shs
Market Capitalization$166.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Competitors

Agile Therapeutics (NASDAQ:AGRX) Vs. EVLO, GOSS, CLVS, XENE, RIGL, and ALBO

Should you be buying AGRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Agile Therapeutics, including Evelo Biosciences (EVLO), Gossamer Bio (GOSS), Clovis Oncology (CLVS), Xenon Pharmaceuticals (XENE), Rigel Pharmaceuticals (RIGL), and Albireo Pharma (ALBO).

Agile Therapeutics (NASDAQ:AGRX) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Profitability

This table compares Agile Therapeutics and Evelo Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agile TherapeuticsN/A-56.84%-45.89%
Evelo BiosciencesN/A-159.17%-88.81%

Analyst Ratings

This is a breakdown of current ratings for Agile Therapeutics and Evelo Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agile Therapeutics00503.00
Evelo Biosciences02302.60

Agile Therapeutics presently has a consensus price target of $8.25, indicating a potential upside of 334.21%. Evelo Biosciences has a consensus price target of $20.00, indicating a potential upside of 79.37%. Given Agile Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Agile Therapeutics is more favorable than Evelo Biosciences.

Valuation & Earnings

This table compares Agile Therapeutics and Evelo Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agile TherapeuticsN/AN/A$-18,610,000.00($0.38)-5.00
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.18

Agile Therapeutics is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Agile Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Insider & Institutional Ownership

44.4% of Agile Therapeutics shares are owned by institutional investors. Comparatively, 84.6% of Evelo Biosciences shares are owned by institutional investors. 4.4% of Agile Therapeutics shares are owned by insiders. Comparatively, 7.3% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Agile Therapeutics beats Evelo Biosciences on 8 of the 11 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Gossamer Bio and Agile Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-64.34%-46.52%
Agile TherapeuticsN/A-56.84%-45.89%

Analyst Ratings

This is a summary of current ratings and price targets for Gossamer Bio and Agile Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00503.00
Agile Therapeutics00503.00

Gossamer Bio currently has a consensus target price of $23.00, indicating a potential upside of 169.64%. Agile Therapeutics has a consensus target price of $8.25, indicating a potential upside of 334.21%. Given Agile Therapeutics' higher probable upside, analysts plainly believe Agile Therapeutics is more favorable than Gossamer Bio.

Valuation & Earnings

This table compares Gossamer Bio and Agile Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.59
Agile TherapeuticsN/AN/A$-18,610,000.00($0.38)-5.00

Agile Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gossamer Bio has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

72.0% of Gossamer Bio shares are held by institutional investors. Comparatively, 44.4% of Agile Therapeutics shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by company insiders. Comparatively, 4.4% of Agile Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Agile Therapeutics beats Gossamer Bio on 5 of the 9 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Clovis Oncology and Agile Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-230.34%N/A-57.56%
Agile TherapeuticsN/A-56.84%-45.89%

Analyst Ratings

This is a summary of current ratings and price targets for Clovis Oncology and Agile Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology22202.00
Agile Therapeutics00503.00

Clovis Oncology currently has a consensus target price of $9.50, indicating a potential upside of 52.00%. Agile Therapeutics has a consensus target price of $8.25, indicating a potential upside of 334.21%. Given Agile Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Agile Therapeutics is more favorable than Clovis Oncology.

Valuation & Earnings

This table compares Clovis Oncology and Agile Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million4.57$-400,420,000.00($7.60)-0.82
Agile TherapeuticsN/AN/A$-18,610,000.00($0.38)-5.00

Agile Therapeutics has lower revenue, but higher earnings than Clovis Oncology. Agile Therapeutics is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

57.8% of Clovis Oncology shares are held by institutional investors. Comparatively, 44.4% of Agile Therapeutics shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by company insiders. Comparatively, 4.4% of Agile Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Agile Therapeutics beats Clovis Oncology on 7 of the 13 factors compared between the two stocks.

Xenon Pharmaceuticals (NASDAQ:XENE) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Xenon Pharmaceuticals and Agile Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xenon Pharmaceuticals00503.00
Agile Therapeutics00503.00

Xenon Pharmaceuticals currently has a consensus target price of $25.25, indicating a potential upside of 29.62%. Agile Therapeutics has a consensus target price of $8.25, indicating a potential upside of 334.21%. Given Agile Therapeutics' higher probable upside, analysts plainly believe Agile Therapeutics is more favorable than Xenon Pharmaceuticals.

Risk and Volatility

Xenon Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

79.9% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Agile Therapeutics shares are held by institutional investors. 8.4% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 4.4% of Agile Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Xenon Pharmaceuticals and Agile Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenon Pharmaceuticals$6.83 million102.13$-41,600,000.00($1.54)-12.65
Agile TherapeuticsN/AN/A$-18,610,000.00($0.38)-5.00

Agile Therapeutics has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xenon Pharmaceuticals and Agile Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xenon Pharmaceuticals-102.25%-21.76%-16.08%
Agile TherapeuticsN/A-56.84%-45.89%

Summary

Agile Therapeutics beats Xenon Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Agile Therapeutics (NASDAQ:AGRX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Agile Therapeutics and Rigel Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agile Therapeutics00503.00
Rigel Pharmaceuticals01302.75

Agile Therapeutics presently has a consensus target price of $8.25, indicating a potential upside of 334.21%. Rigel Pharmaceuticals has a consensus target price of $8.3333, indicating a potential upside of 123.41%. Given Agile Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Agile Therapeutics is more favorable than Rigel Pharmaceuticals.

Risk & Volatility

Agile Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Insider and Institutional Ownership

44.4% of Agile Therapeutics shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 4.4% of Agile Therapeutics shares are held by insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Agile Therapeutics and Rigel Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agile TherapeuticsN/AN/A$-18,610,000.00($0.38)-5.00
Rigel Pharmaceuticals$59.29 million10.70$-66,890,000.00($0.40)-9.33

Agile Therapeutics has higher earnings, but lower revenue than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agile Therapeutics and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agile TherapeuticsN/A-56.84%-45.89%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Summary

Agile Therapeutics beats Rigel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Agile Therapeutics (NASDAQ:AGRX) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Agile Therapeutics and Albireo Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agile Therapeutics00503.00
Albireo Pharma00803.00

Agile Therapeutics presently has a consensus target price of $8.25, indicating a potential upside of 334.21%. Albireo Pharma has a consensus target price of $72.00, indicating a potential upside of 122.29%. Given Agile Therapeutics' higher probable upside, research analysts plainly believe Agile Therapeutics is more favorable than Albireo Pharma.

Risk & Volatility

Agile Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Insider and Institutional Ownership

44.4% of Agile Therapeutics shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 4.4% of Agile Therapeutics shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Agile Therapeutics and Albireo Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agile TherapeuticsN/AN/A$-18,610,000.00($0.38)-5.00
Albireo Pharma$9.64 million64.22$-62,720,000.00($5.04)-6.43

Agile Therapeutics has higher earnings, but lower revenue than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agile Therapeutics and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agile TherapeuticsN/A-56.84%-45.89%
Albireo Pharma-751.53%-71.22%-42.91%


Agile Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.15+11.7%$664.02 millionN/A-4.48Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.53+1.4%$653.32 millionN/A-2.40Increase in Short Interest
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.25+1.8%$653.31 million$143.01 million-1.19
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.48+7.0%$648.86 million$6.83 million-20.08News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.73+3.2%$634.55 million$59.29 million-24.87Increase in Short Interest
News Coverage
Gap Up
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.39+0.6%$622.54 million$9.64 million-5.28News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.90+7.2%$621.98 million$5.09 million-6.50Analyst Downgrade
News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.92+4.9%$605.76 million$12.69 million-11.98Increase in Short Interest
OrganiGram logo
OGI
OrganiGram
1.6$2.60+11.9%$603.91 million$64.61 million-3.82Earnings Announcement
Analyst Report
Decrease in Short Interest
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$37.00+2.8%$602.22 millionN/A-17.13
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.80+0.8%$589.46 million$17.26 million-3.83Analyst Revision
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.79+3.6%$584.23 millionN/A-9.99Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$43.37+2.9%$573.22 million$195.89 million123.92
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.64+3.4%$567.03 millionN/A-5.42Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.27+3.6%$561.28 million$8 million-7.85
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.85+4.6%$543.18 millionN/A-4.28
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.01+4.0%$541.92 millionN/A-4.77
Inventiva logo
IVA
Inventiva
0.0$13.60+2.9%$540.43 millionN/A0.00News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.99+0.6%$539.54 million$26.74 million17.48
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.75+3.3%$536.73 millionN/A-9.11Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.42+2.4%$529.13 million$1.19 million-6.84
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.91+7.7%$519.95 millionN/A-8.23Gap Down
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.98+2.6%$519.55 millionN/A-5.63
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.15+0.5%$516.80 million$25 million-18.69Analyst Report
Provention Bio logo
PRVB
Provention Bio
1.6$8.13+4.6%$515.24 millionN/A-5.46Analyst Report
Increase in Short Interest
Evolus logo
EOLS
Evolus
1.3$11.72+0.5%$509.93 million$34.92 million-5.77Analyst Report
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78+2.7%$499.29 million$59.22 million43.90
XBiotech logo
XBIT
XBiotech
1.0$16.89+1.2%$497.56 millionN/A1.17
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.89+1.2%$492.23 million$58.12 million-16.15Decrease in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$36.38+4.8%$491.46 million$40,000.00-1.58Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.22+0.8%$490.51 million$49.65 million-1.72Analyst Upgrade
Akouos logo
AKUS
Akouos
1.6$14.36+1.3%$487.82 millionN/A0.00News Coverage
Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.95+2.2%$481.09 million$5.80 million-6.51Increase in Short Interest
AC Immune logo
ACIU
AC Immune
1.3$6.87+2.9%$479.82 million$111.75 million-7.63Gap Down
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.20+0.2%$476.23 millionN/A-2.49
89bio logo
ETNB
89bio
1.6$23.78+1.1%$468.93 millionN/A-4.71
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.38+0.3%$468.04 million$72.96 million-3.03Analyst Report
News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.34+13.6%$467.89 million$36.63 million-5.11News Coverage
Gap Up
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.22+5.4%$467.74 million$57.49 million-6.07Increase in Short Interest
Gap Down
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.12+2.9%$465.11 million$335 million-1.05
Verastem logo
VSTM
Verastem
1.3$2.68+0.7%$463.50 million$17.46 million-1.90Analyst Revision
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.25+4.6%$462.43 million$22.27 million-4.04Insider Buying
BCEL
Atreca
1.7$12.42+6.4%$457.44 millionN/A-4.40News Coverage
Gap Down
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.98+0.7%$455.80 million$109.33 million-2.19Analyst Report
Gap Down
Geron logo
GERN
Geron
1.4$1.51+5.3%$455.50 million$460,000.00-4.31Decrease in Short Interest
News Coverage
Gap Down
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.46+1.8%$454.75 million$102.31 million6.66Increase in Short Interest
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.56+3.2%$446.09 million$56.50 million0.00
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.00+1.7%$444.80 millionN/A-12.24
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.89+1.1%$443.24 millionN/A0.00News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.